Clinical Trial

Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME

Study acronym: Tejas
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 4, 2025 (before its estimated May 9, 2025 completion). Its status may not reflect the trial's current state.
Summary
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-05-19; most recent amendment 2025-05-01.
Status change: Recruiting → Active, Not Recruiting 2024-08-13
Status change: Not Yet Recruiting → Recruiting 2022-07-12
Trial Details
NCT Number NCT05387837
Lead Sponsor Ashvattha Therapeutics, Inc.
Conditions Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Enrollment 50 participants
Start Date 2022-08-31
Primary Completion 2025-05-09 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-04